The Food and Drug Administration has awarded Engility (NYSE: EGL) a potential five-year, $112 million indefinite-delivery/indefinite-quantity contract to provide computational
The U.S. Army has announced a $497 million Omnibus III indefinite-delivery/indefinite-quantity contract to support U.S. Navy medicine research and development